The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunityChristina K. Baumgartner, Joshua H. Decker, Hakimeh Ebrahimi-Nik et al.|Nature|2023Cited by 170
Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody–Drug ConjugatesJeffrey C. Kern, R. M. Garbaccio, Jeffrey Zhang et al.|Journal of the American Chemical Society|2016Cited by 141
Development of Anti-CD74 Antibody–Drug Conjugates to Target Glucocorticoids to Immune CellsPhilip E. Brandish, Mark Zielstorff, Anthony Palmieri et al.|Bioconjugate Chemistry|2018Cited by 58
Abstract ND06: ABBV-CLS-484: An active site PTPN2/N1 inhibitor that augments the immune response and sensitizes tumors to immune-mediated killingChristina K. Baumgartner, Philip R. Kym, Marcia N. Paddock et al.|Cancer Research|2022Cited by 7
1365 An active site PTPN2/N1 small molecule inhibitor promotes anti-tumor efficacy by sensitizing tumor cells to inflammatory signals and enhancing immune cell activityKathleen A. McGuire, Philip R. Kym, Christina K. Baumgartner et al.|Regular and Young Investigator Award Abstracts|2022Cited by 1